Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-α (IFN-α) in Operable Renal Cell Carcinoma (RCC)-Reference-Cited by-同舟云学术

Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-α (IFN-α) in Operable Renal Cell Carcinoma (RCC)

Published:2014-11 Issue:9 Volume:37 Page:440-447
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Passalacqua Rodolfo,Caminiti Caterina,Buti Sebastiano,Porta Camillo,Camisa Roberta,Braglia Luca,Tomasello Gianluca,Vaglio Augusto,Labianca Roberto,Rondini Ermanno,Sabbatini Roberto,Nastasi Giuseppe,Artioli Fabrizio,Prati Andrea,Potenzoni Michele,Pezzuolo Debora,Oliva Elena,Alberici Federico,Buzio Carlo

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference2 articles.

1. Cancer Statistics, 2013.;Siegel;CA Cancer J Clin,2013

2. Adjuvant chemotherapy for non-small-cell lung cancer: the end of the beginning.;Johnson;J Natl Cancer Inst,2003

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular understanding and clinical outcomes of CAR T cell therapy in the treatment of urological tumors;Cell Death & Disease;2024-05-24

2. Perioperative systemic treatments in renal cell carcinoma;Frontiers in Oncology;2024-05-21

3. Emerging Strategies in Adjuvant Immunotherapy: A Comparative Review of Bladder Cancer and Renal Cell Carcinoma Treatments;Clinical Medicine Insights: Oncology;2024-01

4. Prognostic Factors and Models for Non-Metastatic Renal Cell Carcinoma;2024

5. Adjuvant therapy for renal cell carcinoma: A systematic review of current landscape and future directions;Critical Reviews in Oncology/Hematology;2023-12